The purpose of this review is to describe the clinical features, pathology and molecular
biology of intraocular lymphomas, which represent a heterogenous group of malignant …

Background The role of BCL2 as a predictor of survival in diffuse large B-cell lymphoma
(DLBCL) is controversial. DLBCL is heterogeneous, and the expression of BCL2 is variable …

The new WHO/EORTC classification for cutaneous lymphomas comprises mature T‐cell and
natural killer (NK)‐cell neoplasms, mature B‐cell neoplasms, and immature hematopoietic …

Purpose We previously determined that intravenous administration of rituximab results in
limited penetration of this agent into the leptomeningeal space. Systemic rituximab does not …

Diffuse large B-cell lymphoma (DLBCL) consists of at least 2 phenotypic subtypes; that is,
the germinal center B-cell–like (GCB-DLBCL) and the activated B-cell–like (ABC-DLBCL) …

Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed
prognostically important subgroups: germinal center B-cell-like (GCB) DLBCL, activated B …

Constitutive activation of the NF-κB pathway is required for survival of the activated B cell–
like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL). Here we show that a small …

The transformation of normal cells into cancer cells and maintenance of the malignant state
and phenotypes are associated with genetic and epigenetic deregulations, altered cellular …

Background Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma
(DLBCL) given a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and …

Chromosomal translocations affecting the MYC oncogene are the biological hallmark of
Burkitt lymphomas but also occur in a subset of other mature B-cell lymphomas. If …